Alnylam Pharmaceuticals (NASDAQ: ALNY) Enters the Obesity Race With First-in-Human Phase 1 Randomized Double-Blind Placebo-Controlled Single-Ascending-Dose Study (NCT07624071) of ALN-6222, an Investigational Subcutaneous siRNA With an Undisclosed Molecular Target Administered as a Single Dose in Adults With Obesity; Trial Enrolls Approximately 88 Participants With BMI 30 to Less Than 40 kg/m² and HbA1c Below 6.5% at a Single Trial Site in Mount Royal, Canada, With Trial Completion Targeted for December 2027
Alnylam Pharmaceuticals (NASDAQ: ALNY) confirmed a first-in-human Phase 1 trial of ALN-6222, an investigational subcutaneous siRNA therapeutic in adults with obesity, in a July 22 filing update on ClinicalTrials.gov (NCT07624071). The randomized, double-blind, placebo-controlled, single ascending dose study will enroll approximately 88 participants with a BMI of 30 to less than 40 kg/m² and an HbA1c below 6.5% (excluding participants with diabetes). The primary endpoints are safety and pharmacodynamics; secondary endpoints include changes in body weight and metabolic markers. The molecular target of ALN-6222 has not been publicly disclosed. The trial is set to run through December 2027 at a single site in Mount Royal, Canada. ALN-6222 marks Alnylam's first clinical-stage entry into the obesity therapeutic area, joining a broader wave of nucleic-acid, peptide, and peptide-fusion modalities entering the space beyond the GLP-1 incumbents (Wegovy, Ozempic, Mounjaro, Zepbound) and the Alnylam-PeptiDream peptide-siRNA conjugate collaboration announced in 2021. Alnylam separately reports Q2 2026 earnings later this week and is expected to discuss the ALN-6222 program on the call.